This American Association for Cancer Research (AACR) conference will convene an extraordinary network of global leaders in basic, translational, and clinical research, together with biopharmaceutical innovators, data scientists, and patient advocates. Over 3 days of interactive plenary sessions, expert panels, and networking forums, the program will spotlight innovative science and collaborative strategies that are transforming the landscape of rare cancer research and care. Participants will explore foundational themes, such as genetic and epigenetic drivers, advanced modeling platforms, novel immunotherapeutics, diagnostic reclassification strategies, and next-generation clinical trial designs, while also gaining insight into how discoveries in rare tumors often catalyze breakthroughs across more common cancers. Throughout, the program will underscore the translational value of rare cancer biology, the urgency of diagnostic equity, and the power of cross-sector partnerships.